La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Marinus Pharma a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Marinus Pharma..

Marinus Pharma (NASDAQ:MRNS) Azioni, Catena delle Opzioni

Marinus Pharma

Marinus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing innovative therapeutics to treat epilepsy and neuropsychiatric disorders. Marinus manages the business in one segment, which is the identification and development of neuropsychiatric therapeutics. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19-RE.

Marinus Pharmaceuticals, Inc. - Common Stock

Marinus Pharmaceuticals Inc

<h3>Gainers</h3>
<ul>
<li>SenesTech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNES#NASDAQ">SNES</a>) stock increased by 9.9% to $3.33 during Tuesday's after-market session. The market value of their outstanding shares is at $3.3 million. </li>
<li>Venus Concept (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERO#NASDAQ">VERO</a>) stock increased by 8.82% to $0.37. The company's market cap stands at $2.6 million. </li>
<li>LogicMark (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGMK#NASDAQ">LGMK</a>) stock moved upwards by 6.3% to $0.12. The market value of their outstanding shares is at $1.4 million. </li>
<li>Marinus Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNS#NASDAQ">MRNS</a>) shares rose 5.37% to $0.31. The company's market cap stands at $16.8 million. </li>
<li>ABVC BioPharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABVC#NASDAQ">ABVC</a>) shares rose 5.33% to $0.74. The company's market cap stands at $9.1 million. </li>
<li>AtriCure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRC#NASDAQ">ATRC</a>) stock rose 5.33% to $31.0. The market value of their outstanding shares is at $1.5 billion. The company's, Q3 earnings came out today. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Tyra Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TYRA#NASDAQ">TYRA</a>) shares declined by 11.2% to $15.01 during Tuesday's after-market session. The company's market cap stands at $792.6 million. </li>
<li>DaVita (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DVA#NYSE">DVA</a>) stock decreased by 8.25% to $145.25. The market value of their outstanding shares is at $12.1 billion. As per the press release, Q3 earnings came out today. </li>
<li>Cyclerion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCN#NASDAQ">CYCN</a>) shares declined by 7.93% to $2.79. The market value of their outstanding shares is at $7.0 million. </li>
<li>Aptevo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APVO#NASDAQ">APVO</a>) shares decreased by 7.7% to $0.28. The market value of their outstanding shares is at $3.7 million. </li>
<li>Reshape Lifesciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RSLS#NASDAQ">RSLS</a>) stock decreased by 7.09% to $5.51. The market value of their outstanding shares is at $2.7 million. </li>
<li>10x Genomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXG#NASDAQ">TXG</a>) stock decreased by 6.59% to $14.75. The market value of their outstanding shares is at $1.7 billion. The company's, Q3 earnings came out today. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

ABVC

APVO

ATRC

CYCN

LGMK

MRNS

RSLS

SNES

TYRA

VERO

12 Health Care Stocks Moving In Tuesday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Evoke Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVOK#NASDAQ">EVOK</a>) stock increased by 128.3% to $12.1 during Monday's pre-market session. The market value of their outstanding shares is at $8.8 million. </li>
<li>Healthcare Triangle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) stock moved upwards by 93.43% to $1.12. The market value of their outstanding shares is at $6.3 million. </li>
<li>Monte Rosa Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLUE#NASDAQ">GLUE</a>) shares rose 30.47% to $6.38. The market value of their outstanding shares is at $391.5 million. </li>
<li>Revance Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVNC#NASDAQ">RVNC</a>) stock increased by 21.06% to $5.69. The company's market cap stands at $592.7 million. </li>
<li>PROCEPT BioRobotics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRCT#NASDAQ">PRCT</a>) stock moved upwards by 14.87% to $79.0. The company's market cap stands at $4.1 billion. The company's, Q3 earnings came out today. </li>
<li>Avalo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVTX#NASDAQ">AVTX</a>) stock rose 14.26% to $16.5. The company's market cap stands at $17.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Koninklijke Philips (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHG#NYSE">PHG</a>) stock decreased by 16.9% to $26.31 during Monday's pre-market session. The market value of their outstanding shares is at $24.5 billion. The company's, Q3 earnings came out today. </li>
<li>Monopar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNPR#NASDAQ">MNPR</a>) stock decreased by 12.88% to $14.75. The company's market cap stands at $51.9 million. </li>
<li>Marinus Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNS#NASDAQ">MRNS</a>) shares declined by 10.84% to $0.36. The market value of their outstanding shares is at $19.8 million. </li>
<li>Aclaris Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACRS#NASDAQ">ACRS</a>) stock declined by 8.29% to $1.55. The company's market cap stands at $110.5 million. </li>
<li>Beyond Air (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XAIR#NASDAQ">XAIR</a>) shares decreased by 7.94% to $0.37. The company's market cap stands at $26.4 million. </li>
<li>Mobile-health Network (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNDR#NASDAQ">MNDR</a>) shares decreased by 7.92% to $0.44. The company's market cap stands at $14.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ACRS

AVTX

EVOK

GLUE

HCTI

MNDR

MNPR

PRCT

RVNC

XAIR

12 Health Care Stocks Moving In Monday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Healthcare Triangle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) stock increased by 93.4% to $1.12 during Monday's pre-market session. The market value of their outstanding shares is at $6.3 million. </li>
<li>Evoke Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVOK#NASDAQ">EVOK</a>) shares rose 71.53% to $9.09. The market value of their outstanding shares is at $6.6 million. </li>
<li>Monte Rosa Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLUE#NASDAQ">GLUE</a>) shares moved upwards by 32.1% to $6.46. The market value of their outstanding shares is at $396.4 million. </li>
<li>Aspira Womens Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AWH#NASDAQ">AWH</a>) shares moved upwards by 22.27% to $1.18. The company's market cap stands at $18.9 million. </li>
<li>Revance Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVNC#NASDAQ">RVNC</a>) stock rose 21.04% to $5.69. The company's market cap stands at $592.6 million. </li>
<li>Mira Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MIRA#NASDAQ">MIRA</a>) stock moved upwards by 15.5% to $1.49. The market value of their outstanding shares is at $22.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Koninklijke Philips (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHG#NYSE">PHG</a>) stock declined by 17.0% to $26.29 during Monday's pre-market session. The market value of their outstanding shares is at $24.5 billion. As per the news, the Q3 earnings report came out today. </li>
<li>Monopar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNPR#NASDAQ">MNPR</a>) stock fell 12.88% to $14.75. The company's market cap stands at $51.9 million. </li>
<li>Marinus Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNS#NASDAQ">MRNS</a>) stock decreased by 10.84% to $0.36. The market value of their outstanding shares is at $19.8 million. </li>
<li>Ensysce Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENSC#NASDAQ">ENSC</a>) stock declined by 9.84% to $0.32. The company's market cap stands at $4.7 million. </li>
<li>Aclaris Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACRS#NASDAQ">ACRS</a>) shares declined by 8.88% to $1.54. The market value of their outstanding shares is at $109.8 million. </li>
<li>Mobile-health Network (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNDR#NASDAQ">MNDR</a>) stock decreased by 8.06% to $0.44. The market value of their outstanding shares is at $14.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ENSC

MIRA

HC Wainwright &amp; Co. analyst Douglas Tsao downgrades Marinus Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNS#NASDAQ">MRNS</a>) from Buy to Neutral.

News

Downgrades

Analyst Ratings

HC Wainwright & Co. Downgrades Marinus Pharma to Neutral

TD Cowen analyst Joseph Thome downgrades Marinus Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNS#NASDAQ">MRNS</a>) from Buy to Hold.

TD Cowen Downgrades Marinus Pharma to Hold

RBC Capital analyst Brian Abrahams maintains Marinus Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNS#NASDAQ">MRNS</a>) with a Sector Perform and lowers the price target from $3 to $1.

Price Target

RBC Capital Maintains Sector Perform on Marinus Pharma, Lowers Price Target to $1

Cantor Fitzgerald analyst Charles Duncan maintains Marinus Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNS#NASDAQ">MRNS</a>) with a Overweight and lowers the price target from $13 to $4.

Cantor Fitzgerald Maintains Overweight on Marinus Pharma, Lowers Price Target to $4

Jefferies analyst Andrew Tsai downgrades Marinus Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNS#NASDAQ">MRNS</a>) from Buy to Hold and lowers the price target from $5 to $0.5.

Jefferies Downgrades Marinus Pharma to Hold, Lowers Price Target to $0.5

U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite gaining over 100 points on Thursday.
The Dow traded down 0.42% to 42,337.45 while the NASDAQ rose 0.65% to 18,396.30. The S&amp;P 500 also rose, gaining, 0.15% to 5,806.21.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41512422/top-3-tech-stocks-youll-regret-missing-in-q4">Top 3 Tech Stocks You&#8217;ll Regret Missing In Q4</a>
Leading and Lagging Sectors Consumer discretionary shares rose by 3.2% on Thursday.
In trading on Thursday, materials shares fell by 1.4%.
Top Headline
Dow Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOW#NYSE">DOW</a>) reported better-than-expected third-quarter results.
Sales rose 1% year over year to $10.88 billion, beating the consensus of $10.65 billion, on higher sales in the U.S. and Canada. Adjusted EPS was $0.47, beating the consensus of $0.46.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Nxu, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXU#NASDAQ">NXU</a>) shares shot up 116% to $0.5406. Nxu and Verde Bioresins reported a proposed merger.</li>
<li>Shares of QuantumScape Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QS#NYSE">QS</a>) got a boost, surging 24% to $6.43 after the company said it has begun producing low volumes of its first B-sample cells and has begun shipping cells for automotive customer testing.</li>
<li>Molina Healthcare, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) shares were also up, gaining 20% to $330.40 after the company reported better-than-expected third-quarter financial results.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Beyond, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BYON#NYSE">BYON</a>) shares dropped 33% to $6.39 after the company reported worse-than-expected third-quarter adjusted EPS and sales.</li>
<li>Shares of Marinus Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNS#NASDAQ">MRNS</a>) were down 82% to $0.3019 after the company announced its Phase 3 TrustTSC trial of Oral Ganaxolone did not meet its primary endpoint.</li>
<li>Community Health Systems, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CYH#NYSE">CYH</a>) was down, falling 23% to $4.29 following third-quarter earnings.</li>
</ul>
Commodities In commodity news, oil traded down 1% to $70.08 while gold traded up 0.7% at $2,748.60.
Silver traded down 0.1% to $33.825 on Thursday, while copper rose 0.6% to $4.3605.
Euro zone
European shares were mostly higher today. The eurozone's STOXX 600 gained 0.03%, Germany's DAX gained 0.34% and France's CAC 40 rose 0.08%. Spain's IBEX 35 Index fell 0.21%, while London's FTSE 100 rose 0.13%.
The S&amp;P Global UK composite PMI declined to 51.7 in October from 52.6 in September, while Eurozone composite edged higher rose to 49.7 in October versus 49.6 in the previous month.
The HCOB Germany composite PMI increased to 48.4 in October versus 47.5 in September, while French composite PMI slipped to 47.3 in October from 48.6 in September.
Asia Pacific Markets
Asian markets closed mostly lower on Thursday, with Japan's Nikkei 225 gaining 0.10%, Hong Kong's Hang Seng Index falling 1.30%, China's Shanghai Composite Index falling 0.68% and India's BSE Sensex falling 0.02%.
The HSBC India composite PMI rose to 58.6 in October from 58.3 in the prior month. The au Jibun Bank Flash Japan composite PMI declined to 49.4 in October compared to a final reading of 52.0 in September.
Economics
<ul>
<li>The Chicago Fed National Activity Index fell to a reading of -0.28 in September compared to a revised level of -0.01 in August.</li>
<li>U.S. initial jobless claims declined by 15,000 from the prior week to 227,000 during the period ending Oct. 19, compared to market estimates of 242,000.</li>
<li>U.S. building permits declined by 3.1% to an annual rate of 1.425 million in September.</li>
<li>The S&amp;P Global flash manufacturing PMI rose to 47.8 in October versus a 15-month low level of 47.3 in September.</li>
<li>The S&amp;P Global services PMI increased to 55.3 in October from 55.2 in the prior month.</li>
<li>Sales of new single-family homes in the U.S. surged 4.1% to an annual rate of 738,000 in September.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41516316/jim-cramer-says-he-would-not-buy-this-health-care-stock-at-this-level-wait-for-a-pullbac">Jim Cramer Says He Would Not Buy This Health Care Stock At This Level: &#8216;Wait For A Pullback&#8217;</a></li>
</ul>

BYON

Crude Oil Down 1%; Dow Posts Upbeat Earnings

JMP Securities analyst Jason Butler downgrades Marinus Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNS#NASDAQ">MRNS</a>) from Market Outperform to Market Perform.

JMP Securities Downgrades Marinus Pharma to Market Perform

On Thursday, Marinus Pharmaceuticals, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNS#NASDAQ">MRNS</a>) stock plunged after the company revealed disappointing data from the Phase 3 TrustTSC trial of oral ganaxolone for seizures associated with tuberous sclerosis complex (TSC) in <a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/b41514570/marinus-pharmaceuticals-announces-topline-results-from-phase-3-trusttsc-trial-of-oral-ganaxolone-i" rel="noreferrer noopener">children and adults</a>.
TSC is a rare genetic condition that mainly causes&nbsp;non-cancerous (benign) tumors to develop in different body parts.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/06/39357270/marinus-pharmaceuticals-shares-mixed-results-from-iv-formulated-ganaxolone-in-pretreated-seizure-" rel="noreferrer noopener">Marinus Pharmaceuticals Shares Mixed Results From IV Formulated Ganaxolone In Pretreated Seizure Patients</a>.
&#8220;As the first controlled trial in TSC that allowed enrollment of patients taking a range of concomitant antiseizure medications, which included mTOR inhibitors and cannabidiol, these data represent a significant advancement in our understanding of the use of ganaxolone with other standard of care treatments,&#8221; said Scott Braunstein, Chairman and CEO of Marinus. &#8220;We are disappointed that the results of the TrustTSC trial are not likely to be sufficient for an sNDA filing.&#8221;
The 129-subject trial did not meet the primary endpoint of percent change in 28-day TSC-associated seizure frequency. Median reduction was 19.7% for ganaxolone compared with 10.2% for placebo (p=0.09).
While reductions in seizure frequency favored the ganaxolone arm, the primary endpoint did not achieve statistical significance.
Ganaxolone was generally well-tolerated with a safety profile consistent with previous clinical trials.
The most frequent adverse event was somnolence: 28.1% for ganaxolone compared with 16.9% for placebo.
Marinus will continue to support and invest in the commercial growth of Ztalmy (ganaxolone) oral suspension CV, which is FDA-approved for seizures associated with CDKL5 deficiency disorder in patients two years and older.
As a result of the TrustTSC outcome, Marinus is discontinuing further ganaxolone clinical development and taking additional steps to reduce costs, including reducing its workforce.
The company has also commenced a process to explore strategic alternatives and has engaged Barclays as an advisor to assist in reviewing its strategic alternatives.
Price Action: MRNS stock is down 82.80% at $0.29 at the last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/10/41516652/honeywells-mixed-q3-eps-beats-misses-on-sales-and-lowers-fy24-revenue-outlook" target="_blank" rel="noreferrer noopener">Honeywell Q3 Earnings: Revenue And Profit Growth, Adjusts Annual Outlook Factoring Acquisitions</a>.</li>
</ul>

Biotech

Health Care

General

Marinus Pharmaceuticals' Oral Seizure Drug Disappoints In Late-Stage Study, Appoints Advisor To Explore Options

U.S. stocks traded mixed midway through trading, with the Nasdaq Composite gaining around 0.3% on Thursday.
The Dow traded down 0.72% to 42,206.88 while the NASDAQ rose 0.26% to 18,323.75. The S&amp;P 500 also fell, dropping, 0.16% to 5,788.23.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41512422/top-3-tech-stocks-youll-regret-missing-in-q4">Top 3 Tech Stocks You&#8217;ll Regret Missing In Q4</a>
Leading and Lagging Sectors Consumer discretionary shares rose by 2.6% on Thursday.
In trading on Thursday, materials shares fell by 1.1%.
Top Headline
Shares of Honeywell International Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HON#NASDAQ">HON</a>) fell around 4% on Thursday after the company reported third-quarter results and updated FY24 guidance.
Revenue grew 6% year-over-year (organic: +3%) to $9.728 billion, missing the consensus of $9.901 billion. Adjusted EPS was $2.58 (+8% Y/Y), beating the consensus of $2.50.
For FY24, the company lowered sales guidance to $38.6 billion – $38.8 billion (from $39.1 billion – $39.7 billion prior) versus the consensus of $39.20 billion. Honeywell tightened adjusted EPS guidance to $10.15 – $10.25 (from $10.05 – $10.25) versus the estimate of $10.13.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Nxu, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXU#NASDAQ">NXU</a>) shares shot up 216% to $0.7930. Nxu and Verde Bioresins reported a proposed merger.</li>
<li>Shares of QuantumScape Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QS#NYSE">QS</a>) got a boost, surging 25% to $6.49 after the company said it has begun producing low volumes of its first B-sample cells and has begun shipping cells for automotive customer testing.</li>
<li>Molina Healthcare, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) shares were also up, gaining 22% to $336.39 after the company reported better-than-expected third-quarter financial results.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Beyond, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BYON#NYSE">BYON</a>) shares dropped 26% to $7.03 after the company reported worse-than-expected third-quarter adjusted EPS and sales.</li>
<li>Shares of Marinus Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNS#NASDAQ">MRNS</a>) were down 80% to $0.3413 after the company announced its Phase 3 TrustTSC trial of Oral Ganaxolone did not meet its primary endpoint.</li>
<li>Community Health Systems, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CYH#NYSE">CYH</a>) was down, falling 23% to $4.2550 following third-quarter earnings.</li>
</ul>
Commodities In commodity news, oil traded down 0.7% to $70.29 while gold traded up 0.4% at $2,741.10.
Silver traded down 0.1% to $33.790 on Thursday, while copper fell 0.1% to $4.3350.
Euro zone
European shares were higher today. The eurozone's STOXX 600 gained 0.25%, Germany's DAX gained 0.54% and France's CAC 40 rose 0.27%. Spain's IBEX 35 Index rose 0.12%, while London's FTSE 100 rose 0.28%.
The S&amp;P Global UK composite PMI declined to 51.7 in October from 52.6 in September, while Eurozone composite edged higher rose to 49.7 in October versus 49.6 in the previous month.
The HCOB Germany composite PMI increased to 48.4 in October versus 47.5 in September, while French composite PMI slipped to 47.3 in October from 48.6 in September.
Asia Pacific Markets
Asian markets closed mostly lower on Thursday, with Japan's Nikkei 225 gaining 0.10%, Hong Kong's Hang Seng Index falling 1.30%, China's Shanghai Composite Index falling 0.68% and India's BSE Sensex falling 0.02%.
The HSBC India composite PMI rose to 58.6 in October from 58.3 in the prior month. The au Jibun Bank Flash Japan composite PMI declined to 49.4 in October compared to a final reading of 52.0 in September.
Economics
<ul>
<li>The Chicago Fed National Activity Index fell to a reading of -0.28 in September compared to a revised level of -0.01 in August.</li>
<li>U.S. initial jobless claims declined by 15,000 from the prior week to 227,000 during the period ending Oct. 19, compared to market estimates of 242,000.</li>
<li>U.S. building permits declined by 3.1% to an annual rate of 1.425 million in September.</li>
<li>The S&amp;P Global flash manufacturing PMI rose to 47.8 in October versus a 15-month low level of 47.3 in September.</li>
<li>The S&amp;P Global services PMI increased to 55.3 in October from 55.2 in the prior month.</li>
<li>Sales of new single-family homes in the U.S. surged 4.1% to an annual rate of 738,000 in September.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41516316/jim-cramer-says-he-would-not-buy-this-health-care-stock-at-this-level-wait-for-a-pullbac">Jim Cramer Says He Would Not Buy This Health Care Stock At This Level: &#8216;Wait For A Pullback&#8217;</a></li>
</ul>

Earnings

Equities

Eurozone

Commodities

Markets

Trading Ideas

Nasdaq Edges Higher; Honeywell Shares Fall After Q3 Results

U.S. stocks traded mixed this morning, with the Dow Jones index falling around 150 points on Thursday.
Following the market opening Thursday, the Dow traded down 0.41% to 42,339.29 while the NASDAQ rose 0.52% to 18,371.25. The S&amp;P 500 also rose, gaining, 0.13% to 5,804.31.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41512422/top-3-tech-stocks-youll-regret-missing-in-q4">Top 3 Tech Stocks You&#8217;ll Regret Missing In Q4</a>
Leading and Lagging Sectors Consumer discretionary shares rose by 2.5% on Thursday.
In trading on Thursday, materials shares fell by 0.7%.
Top Headline
After the closing bell on Wednesday, Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) reported stronger-than-expected earnings for its third quarter, while sales missed estimates.
The automaker reported third-quarter earnings per share of 72 cents, beating a Street consensus estimate of 58 cents per share
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Nxu, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXU#NASDAQ">NXU</a>) shares shot up 233% to $0.8444. Nxu and Verde Bioresins reported a proposed merger.</li>
<li>Shares of Linkage Global Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGCB#NASDAQ">LGCB</a>) got a boost, surging 123% to $0.5889. Linkage Global recently appointed Hanson Ji as new Chief Financial Officer.</li>
<li>TuanChe Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TC#NASDAQ">TC</a>) shares were also up, gaining 93% to $2.80.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Orangekloud Technology Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORKT#NASDAQ">ORKT</a>) shares dropped 76% to $1.80.</li>
<li>Shares of Marinus Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNS#NASDAQ">MRNS</a>) were down 72% to $0.4654 after the company announced its Phase 3 TrustTSC trial of Oral Ganaxolone did not meet its primary endpoint.</li>
<li>Lilium N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LILM#NASDAQ">LILM</a>) was down, falling 58% to $0.23.</li>
</ul>
Commodities In commodity news, oil traded up 0.5% to $71.15 while gold traded up 0.9% at $2,752.60.
Silver traded up 1.2% to $34.235 on Thursday, while copper rose 0.5% to $4.3600.
Euro zone
European shares were higher today. The eurozone's STOXX 600 gained 0.5%, Germany's DAX gained 0.8% and France's CAC 40 rose 0.7%. Spain's IBEX 35 Index rose 0.3%, while London's FTSE 100 rose 0.6%.
The S&amp;P Global UK composite PMI declined to 51.7 in October from 52.6 in September, while Eurozone composite edged higher rose to 49.7 in October versus 49.6 in the previous month.
The HCOB Germany composite PMI increased to 48.4 in October versus 47.5 in September, while French composite PMI slipped to 47.3 in October from 48.6 in September.
Asia Pacific Markets
Asian markets closed mostly lower on Thursday, with Japan's Nikkei 225 gaining 0.10%, Hong Kong's Hang Seng Index falling 1.30%, China's Shanghai Composite Index falling 0.68% and India's BSE Sensex falling 0.02%.
The HSBC India composite PMI rose to 58.6 in October from 58.3 in the prior month. The au Jibun Bank Flash Japan composite PMI declined to 49.4 in October compared to a final reading of 52.0 in September.
Economics
<ul>
<li>The Chicago Fed National Activity Index fell to a reading of -0.28 in September compared to a revised level of -0.01 in August.</li>
<li>U.S. initial jobless claims declined by 15,000 from the prior week to 227,000 during the period ending Oct. 19, compared to market estimates of 242,000.</li>
<li>U.S. building permits declined by 3.1% to an annual rate of 1.425 million in September.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41516316/jim-cramer-says-he-would-not-buy-this-health-care-stock-at-this-level-wait-for-a-pullbac">Jim Cramer Says He Would Not Buy This Health Care Stock At This Level: &#8216;Wait For A Pullback&#8217;</a></li>
</ul>

LGCB

LILM

ORKT

TSLA

Dow Falls 150 Points; Tesla Posts Upbeat Earnings

EF Hutton analyst Jason Kolbert maintains Marinus Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNS#NASDAQ">MRNS</a>) with a Buy and lowers the price target from $23 to $3.

EF Hutton Maintains Buy on Marinus Pharma, Lowers Price Target to $3

WIIM

Marinus Pharmaceuticals shares are trading lower after the company announced its Phase 3 TrustTSC trial of Oral Ganaxolone did not meet its primary endpoint.

Trading Halt: Halt status updated at 8:25:00 AM ET: Quotation Resumption: News and Resumption Times

Marinus Pharmaceuticals Reports Phase 3 TrustTSC Trial Of Oral Ganaxolone In Tuberous Sclerosis Complex Did Not Meet Primary Endpoint; Begins Exploring Strategic Alternatives, Implements Cost Reduction Measures And Workforce Cuts

Marinus Pharmaceuticals Shares Halted Pending News

Trading Halt: Halted at 7:55:00 a.m. ET - Trading Halt: Halt News Pending

EF Hutton analyst Jason Kolbert maintains Marinus Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNS#NASDAQ">MRNS</a>) with a Buy and maintains $23 price target.

EF Hutton Maintains Buy on Marinus Pharma, Maintains $23 Price Target

EF Hutton analyst Jason Kolbert lowered the firm's price target on Marinus Pharmaceuticals (MRNS) to $3 from $23 and keeps a Buy rating on the shar...

Marinus Pharmaceuticals price target lowered to $3 from $23 at EF Hutton

TD Cowen analyst Joseph Thome downgraded Marinus Pharmaceuticals (MRNS) to Hold from Buy without a price target after the Phase III trial of ganaxo...

Marinus Pharmaceuticals downgraded to Hold from Buy at TD Cowen

Marinus (MRNS – Research Report) received a Hold rating and price target from TD Cowen analyst Joseph Thome today. The company's shares closed toda...

TD Cowen downgrades Marinus (MRNS) to a Hold

Jefferies downgraded Marinus Pharmaceuticals (MRNS) to Hold from Buy with a price target of 50c, down from $5. The company's Phase III study of ora...

Marinus Pharmaceuticals downgraded to Hold from Buy at Jefferies

Warning: MRNS is at high risk of performing badly

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Integer Holdings (ITGR – Research Report), Marinus (...

Analysts Offer Insights on Healthcare Companies: Integer Holdings (ITGR), Marinus (MRNS) and Community Health (CYH)

RBC Capital analyst Brian Abrahams maintained a Hold rating on Marinus (MRNS – Research Report) yesterday and set a price target of $1.00. The comp...

Marinus (MRNS) Receives a Hold from RBC Capital

Cantor Fitzgerald analyst Charles Duncan lowered the firm's price target on Marinus Pharmaceuticals (MRNS) to $4 from $13 and keeps an Overweight r...

Marinus Pharmaceuticals price target lowered to $4 from $13 at Cantor Fitzgerald

RBC Capital lowered the firm's price target on Marinus Pharmaceuticals (MRNS) to $1 from $3 and keeps a Sector Perform rating on the shares. The co...

Marinus Pharmaceuticals price target lowered to $1 from $3 at RBC Capital

Catalyst Watch: Eyes on tech with Apple, Amazon, Alphabet, and Meta reporting

AAPL

AMZN

BMEA

CHTR

DASH

FFIV

FVRR

GOOG

HSBC

IDCC

INTC

INUV

ITGR

LFVN

LMND

MGPI

MSFT

OSTX

PAPL

PHUN

PTON

QRVO

RDDT

RKLB

RMLFF

SABR

SAVE

SBUX

SNAP

SVCO

TLTFF

UBER

WHLR

XPEV

Press Releases

Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2024 Financial Results

Marinus Pharmaceuticals to Host Investor and Analyst Day on Friday, September 20, 2024

Marinus Pharmaceuticals to Present at the 2024 Cantor Global Healthcare Conference

Marinus Pharmaceuticals Announces Agenda and Speakers for Investor & Analyst Day on September 20, 2024

Marinus Pharmaceuticals to Highlight Clinical Progress and Commercial Launch Preparedness for ZTALMY® in TSC at Investor and Analyst Day

Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Marinus Pharmaceuticals Announces Podium and Poster Presentations at the Neurocritical Care Society 2024 Annual Meeting

Marinus Pharmaceuticals Further Strengthens Intellectual Property Estate with Method of Treatment Patent for ZTALMY® Titration Regimens

Marinus Pharmaceuticals Presents Clinical Data From Pivotal Phase 3 RAISE Trial in Refractory Status Epilepticus at the Neurocritical Care Society 2024 Annual Meeting

Marinus Pharmaceuticals Announces Topline Results From Phase 3 TrustTSC Trial of Oral Ganaxolone in Tuberous Sclerosis Complex and Commences Process to Explore Strategic Alternatives

Comments

Marinus Pharma

Marinus Pharma (MRNS) Opzioni

Marinus Pharma (NASDAQ:MRNS) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO